October 10, 2024 10:40 PM EDTUpdated 06:31 AM
R&D

Sanofi dis­con­tin­ues De­nali-part­nered MS tri­al af­ter Phase 2 fail­ure

Max Bayer

Pharma Reporter

Sanofi is end­ing a Phase 2 clin­i­cal tri­al that’s test­ing a drug from De­nali for mul­ti­ple scle­ro­sis, putting a stop to the de­vel­op­ment plan. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

A service from the Financial Times